EuroPCR 2022, the world's leading live course in the area of intervention, will be held over four days from May 17th - 20th. In 2020 and 2021, the on-site event was cancelled due to the spread of COVID-19, and only an online course was held, but this year the event will be a hybrid of on-site and partially webcast at the Palais des congrès de Paris.
Late-Breaking Trials Abstracts Presented at EuroPCR 2022
The website announced, “EuroPCR is back in Paris!” as it was held for the first time in three years and featured a live broadcast of the Hot Lines/Late-Breaking Trials sessions, as well as more than 290 interventional sessions on coronary valvular disease, peripheral arteries, hypertension, stroke, and heart failure interventions across 21 venues. Live webcasts will be available from two facilities in France, one in Spain, and one in the UK.
In addition to on-site registration, this year's digital package is €520, and purchasers will have access to all on-demand videos and live course contents for three months after the end of the exhibition.
This year, 1,680 abstracts were received from the public, and there will be 7 sessions for Hot Lines and Late-Breaking Trials. Some of the abstracts scheduled for presentation are listed below;
- Heart Team Decision-Making Based on Contrast-Based FFR: DECISION QFR Trial
- Safety and Efficacy in Post-PCI Physiological Assessment: PROPHET-FFR Trial
- Contrast-Based Assessment of Coronary Microcirculation in INOCA Patients
- Short-Term DAPT in Patients at High Bleeding Risk
- CAG/PCI with Distal Radial Artery Vs. Radial Artery Access
- 5-Year Results for EES Vs. BES: SORT OUT VIII Trial
- BVS Vs. DES in Diabetic Patients: COMPARE-ABSORB Trial Sub-Analysis
- Resolute Onyx for LM Lesions: ROLEX Trial
- Impact of Side Branch Disease Patterns on Outcomes after LM-PCI
- Sirolimus-Coated Balloon 2-Year Results
- Combined DCB and DES for Diffuse Coronary Artery Disease
- Impact of Standardized Procedures and Care Pathways in TAVR: OPTIMIZE PRO Trial
- Prosthesis-Patient Mismatch after TAVR
- Outcomes of Complete Revascularization in TAVR Patients
- Predictors of Death in Patients with Successful TAVR: GALILEO Trial
- Valve-in-Valve TAVR: Balloon-Expandable Valves Vs. Self-Expanding Valves
- MitraClip in Patients with Functional Mitral Regurgitation
- MitraClip as a Bridge to Heart Transplantation
※コンテンツには、国内で未承認、適応外の医療機器、医薬品、または効能・効果/用法・用量の情報を含む場合がありますが、未承認、適応外の使用を推奨するものではありません。
ご注意 当サイト内の全ての記事と動画の転載・転送はご遠慮ください。なお、法律上保護されたコンテンツの無許可の転載、複製、転用等は、当該コンテンツの権利者等から損害賠償請求その他の法的手続を申し立てられ、事案によっては処罰される可能性、また、故意にそれらを受け取った場合も同様の措置を受ける可能性がございます。ご不明な点がございましたら当社までご連絡ください。
おすすめ
